January 25, 2019

Deal Snapshot: GlaxoSmithKline & TESARO

Median oncology acquisition value per quarter

  • Deal Headline: GSK completes acquisition of TESARO (22 Jan 2019)
  • Deal Type: Acquisition
  • Acquirer: GlaxoSmithKline
  • Target: TESARO
  • Therapeutic Area: Oncology
  • Total Deal Size: USD 5100M

GlaxoSmithKline Key BD Contacts

  • Senior Vice President, Head of Business Development | Kevin Sin
  • Executive Director, Corporate and Business Development | Ian Greenberg
  • Vice President and Head of Business Development, North America | Kristen Slaoui

Recent deals:


Business profiles tailored to your asset.